

GSK plc (the 'Company')
**Vesting of Deferred Annual Bonus Plan Deferred Bonus Awards and Sale of Ordinary Shares and American
Depository Shares**

This notification sets out the vesting details for Persons Discharging Managerial Responsibilities ('PDMRs') of Deferred Bonus Awards over Ordinary Shares and American Depository Shares ('ADSs') made in 2021 under the GlaxoSmithKline 2017 Deferred Annual Bonus Plan ('DABP') and subsequent sale of Ordinary Shares and ADSs to meet tax liabilities. In accordance with the shareholder approved 2017 Remuneration Policy and the DABP rules, the awards comprised a mandatory bonus deferral only. The three-year restricted period for the awards commenced on 10 February 2021 and ended on 12 February 2024. Dividends accrued on the awards during the restricted period.

The awards were granted in 2021 as restricted awards over ADSs for US participants and as nil-cost options over Ordinary Shares for all other participants.

The closing prices of Ordinary Shares and of ADSs of GlaxoSmithKline plc on 12 February 2024 were £16.264 and \$41.07.

Transaction notification

1.	Details of PDMR/person closely associated with them ('PCA')		
a)	Name	Emma Walmsley	
b)	Position/status	Chief Executive Officer	
c)	Initial notification/ amendment	Initial notification	
2.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor		
a)	Name	GSK plc	
b)	LEI	5493000HZTVUYLO1D793	
3.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted		
a)	Description of the financial instrument	Ordinary shares of 31 ¼ pence each ('Ordinary Shares') ISIN: GB00BN7SWP63	
b)	Nature of the transaction	The vesting of an award in the form of a nil-cost option over Ordinary Shares granted in 2021 under the Company's 2017 Deferred Annual Bonus Plan and the subsequent exercise of the nil-cost option	
c)	Price(s) and volume(s)	Price(s)	Volume(s)
		£0.00	52,435
d)	Aggregated information	N/A (single transaction)	
	Aggregated volume Price		
e)	Date of the	2024-02-12	

	transaction	
f)	Place of the transaction	N/A

1.	Details of PDMR/person closely associated with them ('PCA')		
a)	Name	Emma Walmsley	
b)	Position/status	Chief Executive Officer	
c)	Initial notification/ amendment	Initial notification	
2.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor		
a)	Name	GSK plc	
b)	LEI	5493000HZTVUYLO1D793	
3.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted		
a)	Description of the financial instrument	Ordinary shares of 31 ¼ pence each ('Ordinary Shares') ISIN: GB00BN7SWP63	
b)	Nature of the transaction	The sale of Ordinary Shares to meet tax liabilities on the exercise of a nil-cost option award granted in 2021 under the Company's 2017 Deferred Annual Bonus Plan	
c)	Price(s) and volume(s)	Price(s)	Volume(s)
		£16.5180	24,682
d)	Aggregated information	N/A (single transaction)	
	Aggregated volume Price		
e)	Date of the transaction	2024-02-12	
f)	Place of the transaction	London Stock Exchange (XLON)	

1.	Details of PDMR/person closely associated with them ('PCA')		
a)	Name	Dr Hal Barron	
b)	Position/status	Non-Executive Director	
c)	Initial notification/ amendment	Initial notification	
2.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor		
a)	Name	GSK plc	
b)	LEI	5493000HZTVUYLO1D793	
3.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted		
a)	Description of the	American Depositary Shares ('ADSs')	

	financial instrument	ISIN: US37733W2044	
b)	Nature of the transaction	The vesting of an award granted in 2021 under the Company's 2017 Deferred Annual Bonus Plan	
c)	Price(s) and volume(s)	Price(s)	Volume(s)
		\$0.00	27,796
d)	Aggregated information	N/A (single transaction)	
	Aggregated volume Price		
e)	Date of the transaction	2024-02-12	
f)	Place of the transaction	N/A	

1.	Details of PDMR/person closely associated with them ('PCA')		
a)	Name	Dr Hal Barron	
b)	Position/status	Non-Executive Director	
c)	Initial notification/ amendment	Initial notification	
2.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor		
a)	Name	GSK plc	
b)	LEI	5493000HZTVUYLO1D793	
3.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted		
a)	Description of the financial instrument	American Depositary Shares ('ADSs') ISIN: US37733W2044	
b)	Nature of the transaction	The sale of ADSs' to meet tax liabilities on the vesting of an award granted in 2021 under the Company's 2017 Deferred Annual Bonus Plan.	
c)	Price(s) and volume(s)	Price(s)	Volume(s)
		\$41.0648	14,941
d)	Aggregated information	N/A (single transaction)	
	Aggregated volume Price		
e)	Date of the transaction	2024-02-12	
f)	Place of the transaction	New York Stock Exchange (XNYS)	

1.	Details of PDMR/person closely associated with them ('PCA')		
-----------	--	--	--

a)	Name	Diana Conrad	
b)	Position/status	Chief People Officer	
c)	Initial notification/ amendment	Initial notification	
2.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor		
a)	Name	GSK plc	
b)	LEI	5493000HZTVUYLO1D793	
3.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted		
a)	Description of the financial instrument	Ordinary shares of 31 ¼ pence each ('Ordinary Shares') ISIN: GB00BN7SWP63	
b)	Nature of the transaction	The vesting of an award in the form of a nil-cost option over Ordinary Shares granted in 2021 under the Company's 2017 Deferred Annual Bonus Plan and the subsequent exercise of the nil-cost option	
c)	Price(s) and volume(s)	Price(s)	Volume(s)
		£0.00	7,600
d)	Aggregated information	N/A (single transaction)	
	Aggregated volume Price		
e)	Date of the transaction	2024-02-12	
f)	Place of the transaction	N/A	

1.	Details of PDMR/person closely associated with them ('PCA')		
a)	Name	Diana Conrad	
b)	Position/status	Chief People Officer	
c)	Initial notification/ amendment	Initial notification	
2.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor		
a)	Name	GSK plc	
b)	LEI	5493000HZTVUYLO1D793	
3.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted		
a)	Description of the financial instrument	Ordinary shares of 31 ¼ pence each ('Ordinary Shares') ISIN: GB00BN7SWP63	
b)	Nature of the transaction	The sale of Ordinary Shares to meet tax liabilities on the exercise of a nil-cost option award granted in 2021 under the Company's 2017 Deferred Annual Bonus Plan	
c)	Price(s) and volume(s)	Price(s)	Volume(s)
		£0.00	1,000

		£16.5104	4,083
d)	Aggregated information	N/A (single transaction)	
	Aggregated volume		
	Price		
e)	Date of the transaction	2024-02-12	
f)	Place of the transaction	London Stock Exchange (XLON)	

1.	Details of PDMR/person closely associated with them ('PCA')		
a)	Name	James Ford	
b)	Position/status	SVP and Group General Counsel, Legal and Compliance	
c)	Initial notification/ amendment	Initial notification	
2.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor		
a)	Name	GSK plc	
b)	LEI	5493000HZTVUYLO1D793	
3.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted		
a)	Description of the financial instrument	Ordinary shares of 31 ¼ pence each ('Ordinary Shares') ISIN: GB00BN7SWP63	
b)	Nature of the transaction	The vesting of an award in the form of a nil-cost option over Ordinary Shares granted in 2021 under the Company's 2017 Deferred Annual Bonus Plan and the subsequent exercise of the nil-cost option	
c)	Price(s) and volume(s)	Price(s)	Volume(s)
		£0.00	9,157
d)	Aggregated information	N/A (single transaction)	
	Aggregated volume		
	Price		
e)	Date of the transaction	2024-02-12	
f)	Place of the transaction	N/A	

1.	Details of PDMR/person closely associated with them ('PCA')		
a)	Name	James Ford	
b)	Position/status	SVP and Group General Counsel, Legal and Compliance	
c)	Initial notification/ amendment	Initial notification	
2.	Details of the issuer, emission allowance market participant, auction platform,		

	auctioneer or auction monitor					
a)	Name	GSK plc				
b)	LEI	5493000HZTVUYLO1D793				
3.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted					
a)	Description of the financial instrument	Ordinary shares of 31 ¼ pence each ('Ordinary Shares') ISIN: GB00BN7SWP63				
b)	Nature of the transaction	The sale of Ordinary Shares to meet tax liabilities on the exercise of a nil-cost option award granted in 2021 under the Company's 2017 Deferred Annual Bonus Plan				
c)	Price(s) and volume(s)	<table border="1"> <thead> <tr> <th>Price(s)</th> <th>Volume(s)</th> </tr> </thead> <tbody> <tr> <td>£16.5056</td> <td>4,319</td> </tr> </tbody> </table>	Price(s)	Volume(s)	£16.5056	4,319
Price(s)	Volume(s)					
£16.5056	4,319					
d)	Aggregated information Aggregated volume Price	N/A (single transaction)				
e)	Date of the transaction	2024-02-12				
f)	Place of the transaction	London Stock Exchange (XLON)				

1.	Details of PDMR/person closely associated with them ('PCA')					
a)	Name	Sally Jackson				
b)	Position/status	SVP, Global Communications and CEO Office				
c)	Initial notification/ amendment	Initial notification				
2.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor					
a)	Name	GSK plc				
b)	LEI	5493000HZTVUYLO1D793				
3.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted					
a)	Description of the financial instrument	Ordinary shares of 31 ¼ pence each ('Ordinary Shares') ISIN: GB00BN7SWP63				
b)	Nature of the transaction	The vesting of an award in the form of a nil-cost option over Ordinary Shares granted in 2021 under the Company's 2017 Deferred Annual Bonus Plan and the subsequent exercise of the nil-cost option				
c)	Price(s) and volume(s)	<table border="1"> <thead> <tr> <th>Price(s)</th> <th>Volume(s)</th> </tr> </thead> <tbody> <tr> <td>£0.00</td> <td>4,627</td> </tr> </tbody> </table>	Price(s)	Volume(s)	£0.00	4,627
Price(s)	Volume(s)					
£0.00	4,627					
d)	Aggregated information Aggregated volume Price	N/A (single transaction)				

e)	Date of the transaction	2024-02-12
f)	Place of the transaction	N/A

1.	Details of PDMR/person closely associated with them ('PCA')					
a)	Name	Sally Jackson				
b)	Position/status	SVP, Global Communications and CEO Office				
c)	Initial notification/ amendment	Initial notification				
2.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor					
a)	Name	GSK plc				
b)	LEI	5493000HZTVUYLO1D793				
3.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted					
a)	Description of the financial instrument	Ordinary shares of 31 ¼ pence each ('Ordinary Shares') ISIN: GB00BN7SWP63				
b)	Nature of the transaction	The sale of Ordinary Shares to meet tax liabilities on the exercise of a nil-cost option award granted in 2021 under the Company's 2017 Deferred Annual Bonus Plan				
c)	Price(s) and volume(s)	<table border="1"> <thead> <tr> <th>Price(s)</th> <th>Volume(s)</th> </tr> </thead> <tbody> <tr> <td>£16.5238</td> <td>2,183</td> </tr> </tbody> </table>	Price(s)	Volume(s)	£16.5238	2,183
Price(s)	Volume(s)					
£16.5238	2,183					
d)	Aggregated information Aggregated volume Price	N/A (single transaction)				
e)	Date of the transaction	2024-02-12				
f)	Place of the transaction	London Stock Exchange (XLON)				

1.	Details of PDMR/person closely associated with them ('PCA')	
a)	Name	Luke Miels
b)	Position/status	Chief Commercial Officer
c)	Initial notification/ amendment	Initial notification
2.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor	
a)	Name	GSK plc
b)	LEI	5493000HZTVUYLO1D793
3.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted	

a)	Description of the financial instrument	Ordinary shares of 31 ¼ pence each ('Ordinary Shares') ISIN: GB00BN7SWP63	
b)	Nature of the transaction	The vesting of an award in the form of a nil-cost option over Ordinary Shares granted in 2021 under the Company's 2017 Deferred Annual Bonus Plan and the subsequent exercise of the nil-cost option	
c)	Price(s) and volume(s)	Price(s)	Volume(s)
		£0.00	14,209
d)	Aggregated information	N/A (single transaction)	
	Aggregated volume Price		
e)	Date of the transaction	2024-02-12	
f)	Place of the transaction	N/A	

1.	Details of PDMR/person closely associated with them ('PCA')		
a)	Name	Luke Miels	
b)	Position/status	Chief Commercial Officer	
c)	Initial notification/ amendment	Initial notification	
2.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor		
a)	Name	GSK plc	
b)	LEI	5493000HZTVUYLO1D793	
3.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted		
a)	Description of the financial instrument	Ordinary shares of 31 ¼ pence each ('Ordinary Shares') ISIN: GB00BN7SWP63	
b)	Nature of the transaction	The sale of Ordinary Shares to meet tax liabilities on the exercise of a nil-cost option award granted in 2021 under the Company's 2017 Deferred Annual Bonus Plan	
c)	Price(s) and volume(s)	Price(s)	Volume(s)
		£16.5020	166
d)	Aggregated information	N/A (single transaction)	
	Aggregated volume Price		
e)	Date of the transaction	2024-02-12	
f)	Place of the transaction	London Stock Exchange (XLON)	

1.	Details of PDMR/person closely associated with them ('PCA')		
-----------	--	--	--

a)	Name	David Redfern	
b)	Position/status	President Corporate Development	
c)	Initial notification/ amendment	Initial notification	
2.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor		
a)	Name	GSK plc	
b)	LEI	5493000HZTVUYLO1D793	
3.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted		
a)	Description of the financial instrument	Ordinary shares of 31 ¼ pence each ('Ordinary Shares') ISIN: GB00BN7SWP63	
b)	Nature of the transaction	The vesting of an award in the form of a nil-cost option over Ordinary Shares granted in 2021 under the Company's 2017 Deferred Annual Bonus Plan and the subsequent exercise of the nil-cost option	
c)	Price(s) and volume(s)	Price(s)	Volume(s)
		£0.00	11,169
d)	Aggregated information	N/A (single transaction)	
	Aggregated volume Price		
e)	Date of the transaction	2024-02-12	
f)	Place of the transaction	N/A	

1.	Details of PDMR/person closely associated with them ('PCA')		
a)	Name	David Redfern	
b)	Position/status	President Corporate Development	
c)	Initial notification/ amendment	Initial notification	
2.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor		
a)	Name	GSK plc	
b)	LEI	5493000HZTVUYLO1D793	
3.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted		
a)	Description of the financial instrument	Ordinary shares of 31 ¼ pence each ('Ordinary Shares') ISIN: GB00BN7SWP63	
b)	Nature of the transaction	The sale of Ordinary Shares to meet tax liabilities on the exercise of a nil-cost option award granted in 2021 under the Company's 2017 Deferred Annual Bonus Plan	

c)	Price(s) and volume(s)	Price(s)	Volume(s)
		£16.5152	5,263
d)	Aggregated information	N/A (single transaction)	
	Aggregated volume Price		
e)	Date of the transaction	2024-02-12	
f)	Place of the transaction	London Stock Exchange (XLON)	

1.	Details of PDMR/person closely associated with them ('PCA')		
a)	Name	Regis Simard	
b)	Position/status	President, Global Supply Chain	
c)	Initial notification/ amendment	Initial notification	
2.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor		
a)	Name	GSK plc	
b)	LEI	5493000HZTVUYLO1D793	
3.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted		
a)	Description of the financial instrument	Ordinary shares of 31 ¼ pence each ('Ordinary Shares') ISIN: GB00BN7SWP63	
b)	Nature of the transaction	The vesting of an award in the form of a nil-cost option over Ordinary Shares granted in 2021 under the Company's 2017 Deferred Annual Bonus Plan and the subsequent exercise of the nil-cost option	
c)	Price(s) and volume(s)	Price(s)	Volume(s)
		£0.00	8,414
d)	Aggregated information	N/A (single transaction)	
	Aggregated volume Price		
e)	Date of the transaction	2024-02-12	
f)	Place of the transaction	N/A	

1.	Details of PDMR/person closely associated with them ('PCA')		
a)	Name	Regis Simard	
b)	Position/status	President, Global Supply Chain	
c)	Initial notification/ amendment	Initial notification	

c)	Initial notification/ amendment	Initial notification				
2.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor					
a)	Name	GSK plc				
b)	LEI	5493000HZTVUYLO1D793				
3.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted					
a)	Description of the financial instrument	Ordinary shares of 31 ¼ pence each ('Ordinary Shares') ISIN: GB00BN7SWP63				
b)	Nature of the transaction	The sale of Ordinary Shares to meet tax liabilities on the exercise of a nil-cost option award granted in 2021 under the Company's 2017 Deferred Annual Bonus Plan				
c)	Price(s) and volume(s)	<table border="1"> <thead> <tr> <th>Price(s)</th> <th>Volume(s)</th> </tr> </thead> <tbody> <tr> <td>£16.4822</td> <td>3,969</td> </tr> </tbody> </table>	Price(s)	Volume(s)	£16.4822	3,969
Price(s)	Volume(s)					
£16.4822	3,969					
d)	Aggregated information	N/A (single transaction)				
	Aggregated volume					
	Price					
e)	Date of the transaction	2024-02-12				
f)	Place of the transaction	London Stock Exchange (XLON)				

1.	Details of PDMR/person closely associated with them ('PCA')					
a)	Name	Phil Thomson				
b)	Position/status	President, Global Affairs				
c)	Initial notification/ amendment	Initial notification				
2.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor					
a)	Name	GSK plc				
b)	LEI	5493000HZTVUYLO1D793				
3.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted					
a)	Description of the financial instrument	Ordinary shares of 31 ¼ pence each ('Ordinary Shares') ISIN: GB00BN7SWP63				
b)	Nature of the transaction	The vesting of an award in the form of a nil-cost option over Ordinary Shares granted in 2021 under the Company's 2017 Deferred Annual Bonus Plan and the subsequent exercise of the nil-cost option				
c)	Price(s) and volume(s)	<table border="1"> <thead> <tr> <th>Price(s)</th> <th>Volume(s)</th> </tr> </thead> <tbody> <tr> <td>£0.00</td> <td>6,532</td> </tr> </tbody> </table>	Price(s)	Volume(s)	£0.00	6,532
Price(s)	Volume(s)					
£0.00	6,532					
d)	Aggregated information	N/A (single transaction)				

	Aggregated volume Price	
e)	Date of the transaction	2024-02-12
f)	Place of the transaction	N/A

1.	Details of PDMR/person closely associated with them ('PCA')		
a)	Name	Phil Thomson	
b)	Position/status	President, Global Affairs	
c)	Initial notification/ amendment	Initial notification	
2.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor		
a)	Name	GSK plc	
b)	LEI	5493000HZTVJYLO1D793	
3.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted		
a)	Description of the financial instrument	Ordinary shares of 31 ¼ pence each ('Ordinary Shares') ISIN: GB00BN7SWP63	
b)	Nature of the transaction	The sale of Ordinary Shares to meet tax liabilities on the exercise of a nil-cost option award granted in 2021 under the Company's 2017 Deferred Annual Bonus Plan	
c)	Price(s) and volume(s)	Price(s) £16.4906	Volume(s) 3,081
d)	Aggregated information Aggregated volume Price	N/A (single transaction)	
e)	Date of the transaction	2024-02-12	
f)	Place of the transaction	London Stock Exchange (XLON)	

1.	Details of PDMR/person closely associated with them ('PCA')		
a)	Name	Deborah Waterhouse	
b)	Position/status	CEO, ViiV Healthcare and President, Global Health, GSK	
c)	Initial notification/ amendment	Initial notification	
2.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor		
a)	Name	GSK plc	
b)	LEI	5493000HZTVJYLO1D793	

3.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted		
a)	Description of the financial instrument	Ordinary shares of 31 ¼ pence each ('Ordinary Shares') ISIN: GB00BN7SWP63	
b)	Nature of the transaction	The vesting of an award in the form of a nil-cost option over Ordinary Shares granted in 2021 under the Company's 2017 Deferred Annual Bonus Plan and the subsequent exercise of the nil-cost option	
c)	Price(s) and volume(s)	Price(s)	Volume(s)
		£0.00	13,426
d)	Aggregated information Aggregated volume Price	N/A (single transaction)	
e)	Date of the transaction	2024-02-12	
f)	Place of the transaction	N/A	

1.	Details of PDMR/person closely associated with them ('PCA')		
a)	Name	Deborah Waterhouse	
b)	Position/status	CEO, Viiv Healthcare and President, Global Health, GSK	
c)	Initial notification/ amendment	Initial notification	
2.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor		
a)	Name	GSK plc	
b)	LEI	5493000HZTVUYLO1D793	
3.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted		
a)	Description of the financial instrument	Ordinary shares of 31 ¼ pence each ('Ordinary Shares') ISIN: GB00BN7SWP63	
b)	Nature of the transaction	The sale of Ordinary Shares to meet tax liabilities on the exercise of a nil-cost option award granted in 2021 under the Company's 2017 Deferred Annual Bonus Plan	
c)	Price(s) and volume(s)	Price(s)	Volume(s)
		£16.5186	6,327
d)	Aggregated information Aggregated volume Price	N/A (single transaction)	
e)	Date of the transaction	2024-02-12	
f)	Place of the transaction	London Stock Exchange (XLON)	

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rs@seg.com or visit www.rs.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our [Privacy Policy](#).

END

DSHSFSFIELSEDE